BRIEFLY : BIOTECHNOLOGY

* MedImmune Inc. will buy cancer drug maker U.S. Bioscience Inc. for about $455 million in stock to speed its entry into the oncology market. MedImmune will exchange 0.15 share for each U.S. Bioscience share. Based on Tuesday’s MedImmune share price of $102.06, the buyout values U.S. Bioscience at $15.31 a share, a 25% premium to its closing price Tuesday of $11.50.